Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 10, 2015

View Archived Issues

Phylogica's 1746-Omomyc fusion reduces tumor size in mouse model of breast cancer

Celyad provides update on C-Cure in Europe

Lundbeck reviews key events of third quarter 2015

Celgene offers pipeline update for third quarter 2015

Investigators present first-in-human results of JF-04 stent for coronary lesions

Squamous NSCLC response rate improved when necitumumab added to paclitaxel-carboplatin

RedHill Biopharma and IntelGenx confirm first European approval of Rizaport

FDA grants breakthrough therapy designation to SD-809 for tardive dyskinesia

Kite Pharma begins phase II trial of KTE-C19 mantle cell lymphoma

PhaseBio begins phase IIa study of once-weekly basal insulin, PE0-139

Caldan Therapeutics finances development of antidiabetic free fatty acid receptor modulators

FDA grants tentative approval to Xtampza for chronic pain

Pivotal phase III trial of RSV-F vaccine in older adults gets started by Novamax

Astellas to establish presence in ophthalmology through acquisition of Ocata Therapeutics

Pfizer reports development of dopamine D1 receptor ligands

Novartis discloses PI3K-gamma inhibitors

Idenix Pharmaceuticals divulges anti-HCV nucleosides

Gruenenthal patents Cav2.2 blockers

AbbVie presents CSF-1R inhibitors

Na-GST-1/Alhydrogel hookworm vaccine well tolerated and immunogenic in phase I studies

Nerviano Medical Sciences characterizes JAK-2 inhibitor NMS-P113

Biosimilar etanercept achieves endpoints in phase III psoriasis study

Fera Pharmaceuticals licenses U.S. rights to NicOx's naproxcinod

Janssen licenses rights to Hanmi's oxyntomodulin-based therapies

New genetic factors linked to persistent ADHD

ATR inhibitor VX-970 in advanced cancer

Proteome Sciences reports data on CK1d inhibitors for Alzheimer's disease

PZ-128 shows clinical promise

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...